Overview
Conference: April 25-27
DIA is offering both a live in-person and a live-stream virtual option for the DIA/FDA Oligonucleotide-Based Therapeutics Conference. Upon registration, please indicate via the check box which avenue you are registering for: in-person or virtual.
Co-sponsored with FDA!
DIA/FDA's Oligonucleotide-based Therapeutics Conference brings together leading experts to inform, educate, and share advancements in oligonucleotide-based therapeutic product development. Developed collaboratively by regulators, industry professionals, and academics, the program covers a wide range of topics from the nonclinical, CMC, and clinical areas. The conference offers a unique experience with multiple perspectives presented, and the opportunity to interface with regulators from around the globe.
Social distancing measures may be in place at the time of the event. Therefore, we encourage you to register and make your housing arrangements early due to potential limited capacity. If the capacity limit is reached, we will only be able to offer the virtual option. Don’t miss out on your chance to meet live again with your friends and colleagues!
We are thrilled to able to offer flexibility to our attendees to attend in-person or virtually. Please note, we are also offering that flexibility to our speakers so you will experience some speakers presenting remotely.
Featured
Want to learn more about DIA/FDA Oligonucleotide-Based Therapeutics Conference? You've come to the right site!
Program Committee
-
Benjamin Stevens, PhD, MPH Director CMC Policy and Advocacy
GlaxoSmithKline, United States -
Scott Henry, PhD Senior Vice President, Nonclinical Development
Ionis Pharmaceuticals, Inc., United States -
Ronald Wange, PhD Associate Director for Pharm/Tox OND
FDA, United States -
Louis St. L. O'Dea, MD Independent Consultant
United States -
Hobart Rogers, PharmD, PhD Pharmacologist
FDA, United States -
Laura Sepp-Lorenzino, PhD Chief Scientific Officer
Intellia Therapeutics, Inc., United States -
Andrew Slugg, MBA, MS Senior Vice President, Global Head of Regulatory Affairs
Alnylam Pharmaceuticals, United States -
Barry Ticho, MD, PhD Chief Medical Officer
Stoke Therapeutics, United States -
Daniel Capaldi, PhD Vice President, Analytical and Process Development
Ionis Pharmaceuticals, Inc, United States -
Monica Cooper, PhD Review Chemist, ONDP, OPQ, CDER
FDA, United States -
Ramin Darvari, PhD, MS Research Fellow
Pfizer Inc., United States -
Ramesh Raghavachari, PhD Supervisor, Unit 3/DPQA IV/OPQA I/OPQ/CDER
FDA, United States -
René Thürmer, PhD Quality Assessor
Federal Institute for Drugs and Medical Devices, Germany -
Patrik Andersson, PhD Senior Director, RNA Therapeutics Safety
AstraZeneca R&D, Sweden -
Elena Braithwaite, PhD Toxicologist
FDA, United States -
Xuan Chi, PhD Supervisory Pharmacologist
CDER, FDA, United States -
David Corey, PhD Professor
UT Southwestern Medical Center at Dallas, United States -
Jeffrey Foy, PhD Senior VP, Toxicology
PepGen Inc., United States -
Aimee L. Jackson, PhD Chief Scientific Officer
Atalanta Therapeutics, United States -
Arthur A. Levin, PhD Distinguished Scientist
Avidity Biosciences, United States -
Emily Place, PhD, MPH Senior Consultant
Aclairo Pharmaceutical Development Group, United States
Have an account?